William Blair & Company
SRPT icon

William Blair & Company’s Sarepta Therapeutics SRPT Stock Holding History

William Blair & Company’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$443K Sell
24,654
-1,036
-4% -$19.6K ﹤0.01% 1276
2026
Q1 		$559K Sell
25,690
-643
-2% -$12.4K ﹤0.01% 1115
2025
Q4 		$567K Sell
26,333
-7,299
-22% -$154K ﹤0.01% 1097
2025
Q3 		$648K Buy
33,632
+6,459
+24% +$115K ﹤0.01% 1036
2025
Q2 		$465K Sell
27,173
-16,942
-38% -$723K ﹤0.01% 1107
2025
Q1 		$2.82M Sell
44,115
-362
-0.8% -$38.1K 0.01% 634
2024
Q4 		$5.41M Sell
44,477
-4,685
-10% -$574K 0.02% 477
2024
Q3 		$6.14M Sell
49,162
-125,120
-72% -$17.3M 0.02% 449
2024
Q2 		$27.5M Buy
174,282
+131,112
+304% +$16.8M 0.08% 172
2024
Q1 		$5.59M Sell
43,170
-1,197
-3% -$147K 0.02% 455
2023
Q4 		$4.28M Sell
44,367
-11,998
-21% -$1.15M 0.01% 491
2023
Q3 		$6.83M Buy
56,365
+9,370
+20% +$1.06M 0.03% 372
2023
Q2 		$5.38M Buy
46,995
+25,983
+124% +$3.35M 0.02% 429
2023
Q1 		$2.9M Sell
21,012
-711
-3% -$92.2K 0.01% 573
2022
Q4 		$2.81M Buy
21,723
+630
+3% +$73K 0.01% 554
2022
Q3 		$2.33M Sell
21,093
-1,020
-5% -$103K 0.01% 577
2022
Q2 		$1.66M Sell
22,113
-8,458
-28% -$622K 0.01% 691
2022
Q1 		$2.39M Sell
30,571
-6,325
-17% -$484K 0.01% 657
2021
Q4 		$3.32M Sell
36,896
-1,903
-5% -$163K 0.01% 588
2021
Q3 		$3.59M Buy
38,799
+4,401
+13% +$339K 0.01% 534
2021
Q2 		$2.67M Buy
34,398
+1,488
+5% +$113K 0.01% 613
2021
Q1 		$2.45M Sell
32,910
-16,654
-34% -$1.54M 0.01% 624
2020
Q4 		$8.45M Buy
49,564
+1,995
+4% +$296K 0.03% 337
2020
Q3 		$6.68M Buy
47,569
+2,746
+6% +$417K 0.03% 340
2020
Q2 		$7.19M Buy
44,823
+5,854
+15% +$797K 0.03% 313
2020
Q1 		$3.81M Buy
38,969
+10,383
+36% +$1.19M 0.02% 389
2019
Q4 		$3.69M Buy
28,586
+1,790
+7% +$181K 0.02% 461
2019
Q3 		$2.02M Buy
26,796
+1,423
+6% +$168K 0.01% 570
2019
Q2 		$3.85M Buy
25,373
+6,230
+33% +$757K 0.02% 428
2019
Q1 		$2.28M Sell
19,143
-4,347
-19% -$559K 0.01% 518
2018
Q4 		$2.56M Sell
23,490
-6,085
-21% -$761K 0.02% 467
2018
Q3 		$4.78M Sell
29,575
-445
-1% -$60.8K 0.03% 379
2018
Q2 		$3.97M Sell
30,020
-3,555
-11% -$335K 0.03% 404
2018
Q1 		$2.49M Sell
33,575
-11,435
-25% -$762K 0.02% 504
2017
Q4 		$2.5M Buy
45,010
+775
+2% +$41.1K 0.02% 521
2017
Q3 		$2.01M Buy
44,235
+27,210
+160% +$1.09M 0.02% 553
2017
Q2 		$574K Buy
+17,025
New +$554K ﹤0.01% 931
2015
Q2 		– Sell
-10,100
Closed -$134K – 2239
2015
Q1 		$134K Sell
10,100
-900
-8% -$12K ﹤0.01% 2046
2014
Q4 		$159K Buy
+11,000
New +$186K ﹤0.01% 1986
2013
Q4 		– Sell
-14,282
Closed -$674K – 2031
2013
Q3 		$674K Buy
14,282
+7,907
+124% +$305K ﹤0.01% 1457
2013
Q2 		$242K Buy
+6,375
New +$228K ﹤0.01% 1754

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

William Blair & Company's SRPT Position: Q2 2026 in Review

William Blair & Company reduced its Sarepta Therapeutics (SRPT) stake by 4% in Q2 2026, selling an estimated $19.6K and leaving 24,654 shares worth $443K. The position accounts for ﹤0.01% of the portfolio, ranked #1276.

William Blair & Company first reported a position in SRPT in Q2 2013 and has held it in 41 quarters since. The position peaked at $27.5M in Q2 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • William Blair & Company held 24,654 shares of Sarepta Therapeutics worth $443K as of Q2 2026.
  • William Blair & Company sold 1,036 Sarepta Therapeutics shares in Q2 2026, an estimated $19.6K.
  • Sarepta Therapeutics made up ﹤0.01% of William Blair & Company's portfolio in Q2 2026, its #1276 holding.
  • William Blair & Company first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 41 quarters since.
  • William Blair & Company's Sarepta Therapeutics position peaked at $27.5M in Q2 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.